NAUT
Nautilus Biotechnology, Inc. NASDAQ Listed Aug 7, 2020$2.33
+1.08%
vs $2.31
Mkt Cap $296.7M
52w Low $0.62
46.5% of range
52w High $4.31
50d MA $2.63
200d MA $2.10
P/E (TTM)
—
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.2x
ROE
-39.5%
P/FCF
-5.6x
RSI (14)
28.30
ATR (14)
$0.15
Beta
0.99
50d MA
$2.63
200d MA
$2.10
Avg Volume
441.7K
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
2701 Eastlake Avenue East · Seattle, WA 98102 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | BMO | -0.14 | -0.12 | +17.2% | 2.57 | +7.8% | +0.8% | -3.5% | +5.2% | +2.7% | +7.0% | — |
| Feb 26, 2026 | BMO | -0.14 | -0.11 | +21.4% | 2.89 | +4.5% | -16.3% | +0.0% | -4.1% | +3.9% | +8.7% | — |
| Oct 27, 2025 | BMO | -0.15 | -0.11 | +26.7% | 1.22 | +0.0% | +10.7% | +5.9% | -1.4% | +0.0% | -5.7% | — |
| Jul 31, 2025 | BMO | -0.15 | -0.12 | +22.6% | 0.76 | +5.1% | +0.0% | +0.6% | -3.0% | +1.3% | +4.9% | — |
| Apr 29, 2025 | BMO | -0.14 | -0.13 | +7.1% | 0.68 | +2.9% | +8.0% | -6.2% | -0.5% | -1.1% | +1.2% | — |
| Feb 26, 2025 | BMO | -0.16 | -0.14 | +12.5% | 1.47 | +0.0% | -2.7% | -18.2% | +11.1% | -4.6% | -2.4% | — |
| Oct 29, 2024 | BMO | -0.17 | -0.13 | +23.5% | 2.81 | -4.6% | -1.4% | -4.3% | -1.9% | +0.4% | -1.5% | — |
| Jul 30, 2024 | BMO | -0.16 | -0.14 | +12.5% | 2.74 | +0.0% | -2.6% | +1.5% | -7.4% | -3.6% | -6.6% | — |
| Apr 30, 2024 | BMO | -0.16 | -0.15 | +6.2% | 2.57 | +3.1% | -1.2% | +9.4% | -4.0% | +0.7% | +4.8% | — |
| Feb 28, 2024 | BMO | -0.16 | -0.14 | +12.5% | 2.94 | -4.8% | -4.8% | -3.9% | +1.1% | -1.1% | -3.0% | — |
| Oct 31, 2023 | BMO | -0.18 | -0.13 | +27.8% | 2.34 | +0.4% | +9.4% | +0.0% | +5.1% | +6.7% | -14.6% | — |
| Aug 2, 2023 | BMO | -0.17 | -0.13 | +23.5% | 3.15 | -4.8% | -2.2% | +1.9% | +1.6% | -5.0% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $2.42 | $2.42 | +0.0% | +0.0% | -4.1% | +3.9% | +8.7% | -6.9% |
| Dec 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $2.23 | $2.20 | -1.3% | -13.9% | +11.5% | +1.4% | -2.8% | -1.4% |
| Aug 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.08 | $3.08 | +0.0% | +1.9% | +1.6% | -5.0% | +2.6% | -0.3% |
| Aug 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.82 | $2.88 | +2.1% | +0.4% | -0.4% | +4.3% | -1.0% | -2.4% |
| Aug 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.82 | $2.88 | +2.1% | +0.4% | -0.4% | +4.3% | -1.0% | -2.4% |
| Jul 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.87 | $2.85 | -0.7% | -4.9% | +0.0% | -4.4% | +6.1% | +3.2% |
| Apr 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $4.19 | $4.27 | +1.9% | -0.7% | -2.6% | -3.5% | +1.0% | +1.5% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.85 | $4.90 | +1.0% | -1.4% | -1.0% | +1.5% | +0.0% | -1.7% |
| Nov 2 | TD Cowen | Maintains | Outperform → Outperform | — | $5.44 | $5.71 | +5.0% | +7.2% | +0.2% | -2.2% | -1.9% | -0.4% |
| Aug 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.65 | $7.56 | -1.2% | -2.1% | +10.1% | -9.3% | +6.7% | -5.0% |
| Jul 13 | Jefferies | Maintains | Buy → Buy | — | $10.00 | $10.16 | +1.6% | -2.0% | -3.4% | -2.7% | -1.0% | -0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | — | Sell | 384,026 | $2.35 | $902K | 971,885 | -10.82% | +1.11% |
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | — | Sell | 4,615,974 | $2.35 | $10.8M | 11,682,032 | -10.82% | +1.11% |
8-K
Nautilus Biotechnology, Inc. -- 8-K Filing
Nautilus Biotechnology shareholders approved annual advisory votes on executive compensation, with the next frequency vote scheduled for 2032, increasing shareholder oversight of management pay practices.
Jun 18
8-K
Nautilus Biotechnolgy, Inc. -- 8-K Filing
Nautilus Biotechnology advanced its single-molecule proteome platform through Tau proteoform analysis and expanded scientific publications, validating technology utility for investors.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Cercano Management Llc | 7,172,985 | $14M | — | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 2,545,597 | $10M | New | Mar 2026 |
| 3 | Clearstead Advisors, Llc | 2,329,784 | $9M | New | Mar 2026 |
| 4 | Millennium Management | 1,273,383 | $5M | Added | Mar 2026 |
| 5 | Acadian Asset Management Llc | 741,246 | $3M | Added | Mar 2026 |
| 6 | Tikvah Management Llc | 726,895 | $3M | — | Mar 2026 |
| 7 | Sentinel Trust Co Lba | 750,000 | $1M | New | Dec 2025 |
| 8 | Marshall Wace, Llp | 319,882 | $1M | Added | Mar 2026 |
| 9 | Renaissance Technologies Llc | 265,700 | $1M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 107,011 | $415K | — | Mar 2026 |
| 11 | Jane Street Group, Llc | 206,837 | $403K | Added | Dec 2025 |
| 12 | Point72 Asset Management | 83,043 | $322K | Added | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 79,623 | $309K | Reduced | Mar 2026 |
| 14 | Barclays Plc | 73,325 | $285K | Added | Mar 2026 |
| 15 | Crewe Advisors Llc | 136,052 | $265K | — | Dec 2025 |
| 16 | Palumbo Wealth Management Llc | 65,231 | $253K | Added | Mar 2026 |
| 17 | Hrt Financial Lp | 65,254 | $253K | New | Mar 2026 |
| 18 | Bank Of America Corp /de/ | 63,147 | $245K | Added | Mar 2026 |
| 19 | Citizens Financial Group Inc/ri | 50,000 | $194K | New | Mar 2026 |
| 20 | Catalyst Funds Management Pty Ltd | 46,328 | $180K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 247,979 | $600K | Feb 2026 |
| 2 | Ultra-Small Company Market Fund | 130,000 | $504K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 81,814 | $198K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 76,105 | $184K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 67,945 | $164K | Feb 2026 |
| 6 | Dimensional U.S. Core Equity 2 ETF | 71,084 | $139K | Jan 2026 |
| 7 | U.S. SMALL CAP PORTFOLIO | 65,776 | $128K | Jan 2026 |
| 8 | SMALL CAP EQUITY FUND | 27,094 | $105K | Mar 2026 |
| 9 | Dimensional U.S. Small Cap ETF | 40,161 | $78K | Jan 2026 |
| 10 | U.S. MICRO CAP PORTFOLIO | 22,900 | $45K | Jan 2026 |
| 11 | LVIP Dimensional U.S. Core Equity 2 Fund | 5,121 | $20K | Mar 2026 |
| 12 | Victory Extended Market Index Fund | 6,171 | $12K | Jan 2026 |
| 13 | Avantis U.S. Small Cap Equity ETF | 518 | $1K | Feb 2026 |
| 14 | Knights of Columbus U.S. ALL CAP INDEX FUND | 248 | $484 | Jan 2026 |
Valuation
Market Cap
$296.7M
Enterprise Value
$214.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.26x
P/B
1.88x
P/S
—
P/FCF
-5.61x
EV/EBITDA
—
Shares Out
126.3M
Financials (TTM)
Revenue
$0
Net Income
-$57.1M
EBITDA
-$50.8M
Free Cash Flow
-$52.0M
Op Cash Flow
-$50.7M
EPS Basic
$-0.47
EPS Diluted
$-0.46
EPS Forward
$-0.52
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$191.1M
Total Liab.
$34.1M
Total Equity
$157.0M
Cash
$103.4M
LT Debt
$26.2M
Book Value/Sh
$1.24
Debt/Equity
0.19x
Current Ratio
13.33
Quick Ratio
13.33
Returns & Growth
ROE
-39.5%
ROA
-32.1%
ROIC
-35.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+16.1%
Price Returns
2W
+4.6%
1M
+4.2%
3M
+13.2%
6M
+21.8%
12M
+266.8%
Technicals
52W High
$4.31
52W Low
$0.62
50d MA
$2.63
200d MA
$2.10
RSI (14)
28.30
ATR (14)
$0.15
Beta
0.99
Avg Volume
442K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.50
High
$2.50
Low
$2.50
Median
$2.50
Data updated apr 26, 2026 2:16pm
· Source: financialmodelingprep.com